Compare JSPR & DUO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | JSPR | DUO |
|---|---|---|
| Founded | 2018 | 2011 |
| Country | United States | China |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Real Estate |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 26.3M | 24.6M |
| IPO Year | 2019 | 2018 |
| Metric | JSPR | DUO |
|---|---|---|
| Price | $14.35 | $0.55 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 321.1K | 29.4K |
| Earning Date | 11-27-2026 | 08-28-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 19.22 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.32 | $0.42 |
| 52 Week High | $17.03 | $2.44 |
| Indicator | JSPR | DUO |
|---|---|---|
| Relative Strength Index (RSI) | 80.68 | 46.95 |
| Support Level | $0.64 | $0.52 |
| Resistance Level | $17.03 | $0.70 |
| Average True Range (ATR) | 1.05 | 0.05 |
| MACD | 1.15 | -0.00 |
| Stochastic Oscillator | 79.63 | 41.68 |
Jasper Therapeutics Inc is a clinical-stage biotechnology company focused on developing therapeutics targeting mast cell driven diseases such as Chronic Spontaneous Urticaria (CSU), Chronic Inducible Urticaria (CIndU) and asthma. The company's lead product candidate, briquilimab, is a monoclonal antibody designed to block stem cell factor (SCF) from binding to and signaling through the CD117 (KIT) receptor on mast and stem cells. The company has a single operating and reportable segment, which is the research and development of therapeutic products in the fields of chronic urticaria and asthma.
Fangdd Network Group Ltd is an investment holding company. It is engaged in the provision of real estate information services through its online platform which also offers integrated marketing services for individual customers, real estate developers, and agents in China. Its SaaS-based solutions help real estate agents to connect with essential business resources, including customers, property listings, capital, and transaction data. The company generates the majority of its revenue from Base commission from transactions in China. All revenues of the Group are derived from the PRC.